Table 2 Studies reporting outcomes of veno-venous ECMO in COVID-19 critically ill adults
Study | Study type | Age | Pre-ECMO MV (days) | ECMO usage | Pre-ECMO PaO2/FiO2 | Prone before ECMO | NMB before ECMO | ECMO duration (days) | Mortality |
|---|---|---|---|---|---|---|---|---|---|
Yang [34] | Retrospective/single center | NA | NA | 6/52 | NA | NA | NA | NA | 83.3% |
Osho [31] | Case series | 47 (43–54) | 5.5 (3.5–6.75) | 6/6 | 95 (84–100) | 100% | 100% | 12 (4–18) | 8%a |
Li [29] | Retrospective/multicenter | 64.3 (± 17.6) | 9.7 (± 5.7) | 8/16 | 66.1 (± 7.8) | NA | NA | 27.1 (± 17.7) | 50%a |
Zhang [126] | Retrospective/single center | NA | NA | 10/221 | NA | NA | NA | NA | 20%a |
Zeng [35] | Retrospective/2 centers | 50.9 (13.5) | NA | 12/12 | NA | NA | NA | 11.3 (± 7.8) | 42%a |
Le Breton [127] | Case series | 50 (43–55) | 6 (4–6) | 13/83 | 59 (54–58) | 100% | 100% | 13 (3–34) | 85% |
Yang [34] | Retrospective/multicenter | 62 (33–78) | 4 (1–7) | 73/73 | 71.9 (59–87) | 58.9% | NA | 18.5 (12–30) | 81%a |
Jacobs [27] | Retrospective/multicenter | 52.4 (± 12.5) | 4 (2.0–6.5) | 32/32 | NA | 62.5% | NA | 6 (5–10) | 31%a |
Lebreton [39] | Retrospective/multicenter | 52 (45–58) | 5 (3–7) | 302/302 | 61 (54–70) | 94% | 96% | 14 (8–26) | 54% |
Kon [28] | Retrospective/single center | 40 (30.5–47) | 2 (1–4) | 27/321 | 84 (70–118) | 82% | 96% | 11 (10–14) | 4%a |
Jacobs [37] | Prospective, multicenter cohort | 51 (41–60) | 4 (1–6) | 100/100 | NA | 70% | NA | 12 (8–22) | 50% |
Schmidt [40] | Retrospective/multicenter | 49 (41–56) | 4 (3–6) | 83/492 | 60 (54–68) | 94% | 96% | 20 (10–40) | 31% |
Barbaro [36] | Retrospective/multicenter | 49 (41–57) | 4 (1.8–6.4) | 1035/1035 | 72 (59–64) | 60% | 72% | 14 (8–23) | 39% |
Mustafa [30] | Retrospective/two centers | 48.4 (± 1.5) | 4 (± 0.5) | 40/40b | NA | 73% | 78% | 13 (± 2.6) | 15% |
Diaz [42] | Retrospective/multicenter | 48 (41–55) | 4 (2–7) | 85/85 | 87 (64–99) | 91.8% | 94.1% | 16 (10–27) | 38.8% |